Related Experiment Videos

Triple combination therapy to improve blood pressure control: experience with

Giuliano Tocci1, Francesco Paneni, Jasmine Passerini

  • 1IRCCS Neuromed, Pozzilli, Italy.

Expert Opinion on Pharmacotherapy
|November 23, 2012
PubMed

Insights

Triple combination therapy using olmesartan, a thiazide diuretic, and a calcium channel blocker effectively controls hypertension. This combination offers sustained blood pressure reduction for a wide range of patients.

Area of Science:

  • Cardiology
  • Pharmacology
  • Nephrology

Background:

  • Hypertension management is crucial for preventing cardiovascular diseases.
  • Despite established strategies, hypertension control remains suboptimal globally.
  • Combination therapy is increasingly recognized as essential for effective hypertension treatment.

Purpose of the Study:

  • To review evidence supporting triple combination therapy for hypertension.
  • To focus on combinations including olmesartan medoxomil, hydrochlorothiazide, and amlodipine besylate.

Main Methods:

  • Overview of existing clinical evidence.
  • Focus on triple therapy with specific antihypertensive drug classes.

Main Results:

  • Triple combination therapy demonstrates significant blood pressure reduction.
  • Effective control of both systolic and diastolic, clinic and ambulatory BP levels.
  • Favorable tolerability and safety profile observed.

Conclusions:

  • Olmesartan-based triple therapy provides effective and sustained blood pressure control.
  • Achieves significant BP reduction in a high proportion of diverse hypertensive patients.
  • Supports the use of this triple combination as a cornerstone treatment strategy.
Abstract

Related Concept Videos

Hypertension IV: Drug Therapy and Lifestyle Modifications01:28

Hypertension IV: Drug Therapy and Lifestyle Modifications

Multiple classes of antihypertensive medications are employed in treating hypertension. The most commonly recommended first-line treatments include:Thiazide Diuretics, such as chlorthalidone, increase sodium and water excretion from the body, reducing blood volume and blood pressure.Angiotensin-converting enzyme inhibitors, like lisinopril, block the conversion of angiotensin I to II, a potent vasoconstrictor lowering blood pressure.Angiotensin II Receptor Blockers (ARBs) prevent angiotensin II...
Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Hypertension III: Clinical Manifestations and Diagnostic Studies01:30

Hypertension III: Clinical Manifestations and Diagnostic Studies

Hypertension is asymptomatic and also referred to as the "silent killer" until it progresses to a severe stage or causes target organ disease. Patients may experience symptoms stemming from the strain on blood vessels and tissues in various organs or the heart's increased workload.Physical exams might show no abnormalities other than high blood pressure. Signs of vascular damage, when present, correspond to the organs supplied by the affected vessels, leading to target organ damage. For...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...